沙库巴曲缬沙坦在心力衰竭中的临床应用  

Overview of the clinical application of Valsartan in heart failure

作　　者：向春林 罗勇[1] Xiang Chunlin;Luo Yong(North Sichuan Medical College,Nanchong,Sichuan 637000,China)

机构地区：[1]川北医学院,四川南充637000

出　　处：《医药前沿》2020年第26期7-9,共3页Journal of Frontiers of Medicine

摘　　要：RAAS系统(Renin-angiotensin-aldosterone system)抑制剂是伴有射血分数下降的心力衰竭(HFrEF,Heart Failure with reduced Ejection Fraction)患者治疗的基石。沙库巴曲缬沙坦由脑啡肽酶抑制剂沙库巴曲和血管紧张素2受体阻滞剂缬沙坦组成,可以同时抑制脑啡肽酶和血管紧张素2受体,与单独抑制RAAS系统系统相比能够更好得改善神经激素的平衡。由于在PARADIGM-HF研究中良好的的有效性和安全性,沙库巴曲缬沙坦已经在主要国际指南中作为新的心力衰竭治疗选择被强烈推荐。本文就沙库巴曲缬沙坦在心力衰竭中的临床应用予以概述。Renin-angiotensin-aldosterone system(RAAS)inhibitors are a cornerstone in the.treatment of heart failure with reduced ejection fraction(HFrEF).Sacubitril/Valsartan is composed of the neprilysin inhibitor Sacubitril and the angiotensin receptor blocker Valsartan.It can inhibit both neprilysin and angiotensin 2 receptors at the same time.Compared with inhibiting the RAAS system alone,it can better improve the balance of neurohormones.Due to its excellent robustness in a PARADIGM-HF trial,Sacubitril/Valsartan has been strongly recommended as a new treatment option for heart failure in major international guidelines.This paper summarizes the clinical application of shakuba-trevalsartan in heart failure.

关 键 词：沙库巴曲缬沙坦 心力衰竭 临床应用 

分 类 号：R541.6[医药卫生—心血管疾病]